Immunic(IMUX)
$7.52-0.27 (-3.47%)
IMUX
Immunic stock drug pipeline
$7.52
At close:-0.27 (-3.47%)
Want to see IMUX full AI Analyst Report?
Immunic (IMUX) Drug Pipeline
2,277 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Imu-838 Tablets | Multiple Sclerosis, Relapsing-Remitting | Phase III | Active Not Recruiting | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Dec 13, 2021 | ― |
| Imu-838 Tablets | Multiple Sclerosis | Phase III | Active Not Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Sep 30, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Imu-838 Tablets | Phase III | Multiple Sclerosis, Relapsing-Remitting | Active Not Recruiting | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Dec 13, 2021 | ― |
| Imu-838 Tablets | Phase III | Multiple Sclerosis | Active Not Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Sep 30, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Immunic, Inc. (IMUX) have in its pipeline
Immunic IMUX is currently developing the following drugs: Imu-838 Tablets. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
